Genetics and gene editing trials

3 studies from 2006 to 2026. Results: 3 safety, side effects or genetics. Every summary comes from the trial's PubMed abstract.

Fewer heart events or deaths
No clear benefit
Lipid or plaque goal met
Safety, side effects or genetics

1984 to 20263 studies, 0 people in trials

Circle size shows how many people took part. Tap a circle to open the trial; on a phone, swipe sideways for earlier years. The people count leaves out meta-analyses and genetic studies, which pool other studies.

All 3 studies

Heart-22026 · VERVE-102 · 35 people
A single intravenous dose of the base-editing drug VERVE-102 produced dose-dependent, durable reductions in PCSK9 and LDL cholesterol, with an acceptable early safety profile, in a small phase 1 trial.
Early safety/biomarker dataGenetics and gene editingInvestigational
Ference 20162016 · PCSK9/HMGCR variants · 112,772 people
Genetic mimicry shows that lowering LDL cholesterol via PCSK9 variants protects against cardiovascular events about as much as HMGCR (statin-target) variants, but both are linked to a smaller, additive increase in diabetes risk.
Supports LDL causalityGenetics and gene editingNot applicable
Cohen 20062006 · PCSK9 variants · 12,887 people
People who naturally carry LDL-lowering PCSK9 gene variants from birth have a dramatically lower lifetime risk of coronary heart disease, supporting that lowering LDL-C, even modestly, over a lifetime substantially cuts cardiovascular risk.
Supports LDL causalityGenetics and gene editingNot applicable

Other medicines

Search and filter all 106 studies in the trial database. Education only, not medical advice.